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Bisphosphonates such as alendronate are antiosteoporotic drugs that inhibit the activity of bone-resorbing osteoclasts and
secondarily promote osteoblastic function. Diabetes increases bone-matrix-associated advanced glycation end products (AGEs)
that impair bone marrow progenitor cell (BMPC) osteogenic potential and decrease bone quality. Here we investigated the
in vitro effect of alendronate and/or AGEs on the osteoblastogenic, adipogenic, and chondrogenic potential of BMPC isolated
from nondiabetic untreated rats. We also evaluated the in vivo effect of alendronate (administered orally to rats with insulin-
deficient Diabetes) on long-bone microarchitecture and BMPC multilineage potential. In vitro, the osteogenesis (Runx2, alkaline
phosphatase, type 1 collagen, and mineralization) and chondrogenesis (glycosaminoglycan production) of BMPC were both
decreased by AGEs, while coincubation with alendronate prevented these effects.The adipogenesis of BMPC (PPAR𝛾, intracellular
triglycerides, and lipase) was increased by AGEs, and this was prevented by coincubation with alendronate. In vivo, experimental
Diabetes (a) decreased femoral trabecular bone area, osteocyte density, and osteoclastic TRAP activity; (b) increased bone
marrow adiposity; and (c) deregulated BMPC phenotypic potential (increasing adipogenesis and decreasing osteogenesis and
chondrogenesis). Orally administered alendronate prevented all these Diabetes-induced effects on bone. Thus, alendronate
could improve bone alterations in diabetic rats by preventing the antiosteogenic, antichondrogenic, and proadipocytic effects of
AGEs on BMPC.
1. Introduction
Bisphosphonates (BPs) have been extensively used to treat
postmenopausal, age-related and steroid-induced osteoporo-
sis, Paget’s disease, and osteolysis-induced hypercalcemia
associated with multiple myeloma and metastatic cancers [1].
The chemical structure of these drugs is similar to inorganic
pyrophosphate: while the latter has a P–O–P bond linking
both phosphate groups, in the former it is replaced by a P–C–
P structure. BPs possess a so-called “bone hook” consisting
of both phosphonate groups, facilitating its binding to bone
mineral [2]. Thus, BPs accumulate rapidly in bone tissue
where they primarily inhibit the activity of bone-resorbing
osteoclasts [1].
Nitrogen-containing bisphosphonates (N-BPs) such as
alendronate are the most potent kind; they inhibit farnesyl
pyrophosphate synthase (FPPS), a key regulatory enzyme in
the mevalonate pathway, and thereby prevent prenylation of
small GTPase signaling proteins. In bone, protein isoprenyla-
tion is essential for osteoclastogenesis and bone resorption [1,
3].Thus, treatmentwithN-BPs is currently themost common
treatment for postmenopausal osteoporosis [1, 3]. In vivo,
treatment with BPs has an antifracture effect via inhibition
of bone resorption and increase in bone mass [3].
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Previous studies suggest that nonresorbing bone cells
such as osteoblasts and osteocytes may also be targets of
BPs action [4]. It has been reported that BPs can inhibit
glucocorticoid-induced apoptosis in these bone cells, a pro-
cess that appears to be mediated by Cx43 hemichannel
aperture [5]. In fact, Cx43 is required for the antiapoptotic
effect of BPs on bone cells, both in vitro and in vivo [6, 7].
During aging and postmenopausal osteoporosis there is
an increase in osteoclastic activity, as well as a shift in the pro-
gression of bone marrow progenitor cells (BMPC) towards
an adipocytic phenotype in detriment of osteoblastogenesis
[8]. This selection of adipogenesis over osteoblastogenesis in
the bone marrow microenvironment has also been reported
in other conditions such as type 1 Diabetes mellitus, in
which there is an accumulation of bone matrix advanced
glycation end products (AGEs) [9, 10]. A crucial step in
the formation of mineralized tissue involves osteoblastic
commitment of BMPC, followed by their mobilization to the
bone surface. Maintenance of bone cell homeostatic balance
depends on adequate cell-matrix and cell-cell interactions
[11]. We have previously shown that high levels of AGEs
accumulated on bone collagen can decrease the integrin-
mediated attachment of osteoblasts to the matrix [12]. We
have also found that soluble and matrix-associated AGEs can
impair osteoblastic growth and differentiation via activation
of RAGE (receptor for AGEs), potentially contributing to dia-
betic osteopenia [13, 14]. Thus, accumulation of bone AGEs
has been implicated in a Diabetes-induced decrease in bone
quality and/or mass, leading to an increase in fracture risk
[15, 16].
An increase in the glycation of bonematrix proteins could
be associated not only with loss of bone quality, but also
with differential responses to antiosteoporotic treatments.
The use of BPs for treatment of diabetic osteopathy is still
an unsolved issue. Although some authors have reported a
BPs-induced improvement in bone mineral density (BMD)
of diabetic postmenopausal women [17, 18], other researchers
have suggested that postmenopausal women with type 2
Diabetes could be resistant to a long-term treatment with
BPs [19]. Interestingly, we have previously found that low
doses (10−8M) of alendronate can completely prevent the
in vitro antiosteogenic and proapoptotic effects of AGEs on
osteoblastic cells [20]. This effect of alendronate is blocked
by nifedipine, an L-type calcium channel inhibitor. Although
this data provides evidence suggesting that BPs could have
indirect anabolic actions on osteoblasts (i.e., blocking AGEs-
induced deleterious effects on this cell type), the effect
of alendronate on BMPC multilineage progression in the
context of an increase in bone AGEs (such as diabetic bone)
remains unknown.
In the present study we have evaluated the in vitro
effect of alendronate and/or AGEs on the osteoblastogenic,
adipogenic, and chondrogenic potential of BMPC obtained
from control rats. We have also investigated the in vivo effect
of alendronate on long-bone microarchitecture in rats with
insulin-deficient Diabetes, as well as the ex vivo action of this
bisphosphonate on BMPC multilineage progression (i.e., the
effect of orally administered alendronate on the osteogenic,
adipocytic, and chondrogenic potential of BMPC obtained ex
vivo from treated animals). In addition, possible mechanisms
of action have been studied.
2. Materials and Methods
2.1. Materials. Alendronate [1-hydroxy-3-aminobutylidene-
1, 1-bisphosphonic acid] was kindly provided by Dr. Hec-
tor Ostrowski of Elea Laboratories (Argentina). Dulbecco’s
modified Eagle’s medium (DMEM) was obtained from Invit-
rogen (Buenos Aires, Argentina), trypsin–EDTA was from
Gibco and fetal bovine serum was obtained from Natocor
(Co´rdoba, Argentina). Tissue culture disposable material
was from Nunc (Tecnolab, Buenos Aires, Argentina). Cen-
tricon 10 kDa cutoff filter cartridges were purchased from
Amicon Inc. (Beverly, MA, USA). Bovine serum albumin,
D-glycolaldehyde, Triton X-100 and Sirius Red dye were
obtained from Sigma-Aldrich (Buenos Aires, Argentina).
Dihydrorhodamine 123 (DHR) was from Molecular Probes
(Buenos Aires, Argentina). All other chemicals and reagents
were purchased from commercial sources and were of analyt-
ical grade.
2.2. Preparation of Advanced Glycation End Products. AGEs-
modified bovine serum albumin (BSA) was prepared by
incubation of 10mg/mL BSA with 33mM D-glycolaldehyde
in 150mMphosphate-buffered saline pH 7.4 at 37∘C for 3 days
under sterile conditions, aswehave previously described [20].
Control BSA was incubated in the same conditions without
sugar. Unincorporated sugar was removed by centrifuga-
tion/filtration with Centricon filter cartridges.The formation
of AGEs was assessed by fluorescence emission at 420 nm
upon excitation at 340 nm. The estimated levels of AGEs-
BSA obtained by this in vitro incubation were 16.9% relative
fluorescence intensity/mg protein, in contrast to 3.7% for
control BSA.
2.3. Animal Treatments. Three-month-old male Sprague-
Dawley rats (190–210 g) were used. Animals were maintained
in a temperature-controlled room at 23∘C, with a fixed
12 h light: 12 h darkness cycle, and fed standard rat laboratory
chow and water ad libitum. All experiments on animals were
done in conformity with the Guidelines on Handling and
Training of LaboratoryAnimals published by theUniversities
Federation for Animals Welfare [21]. Approval for animal
studies was obtained from our institutional animal welfare
committee (Protocol Number 001-05-15).
For in vitro studies, control (nondiabetic untreated)
animals were used as a source of BMPC. Briefly, they were
sacrificed under anaesthesia by rapid cervical dislocation.
Bone marrow cells were collected by flushing the femoral
diaphysis medullary canal with Dulbecco’s modified essential
medium (DMEM) under sterile conditions and processed as
described in the following sections.
To perform in vivo and ex vivo studies, 16 animals
were submitted to i.p injection of nicotinamide (50mg/kg
in physiological saline) followed by i.p. streptozotocin
(60mg/kg freshly dissolved in 0.05M citrate buffer pH 4.5) in
order to induce partially insulin-deficient Diabetes mellitus
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[22, 23], while another group of 16 rats was allowed to
remain nondiabetic. A week later, nonfasting blood glucose
(Wiener, Rosario, Argentina) and insulin (ALPCO, USA)
were assayed according to instructions of the manufacturer,
in order to verify the metabolic status of animals. Control
animals showed the following results: 1.35 ± 0.15 ng/mL for
insulin and 171 ± 8mg/dL for glucose. Results for diabetic
animals were 0.25±0.09 ng/mL for insulin and 433±22mg/dL
for glucose. Rats were then subdivided into four groups
of eight animals per group: control (nontreated nondia-
betic) (C) and untreated diabetic rats (D) received water ad
libitum, whereas alendronate-treated nondiabetic (CA) and
alendronate-treated diabetic (DA) rats received 1mg/kg/day
of alendronate (Elea Lab., Buenos Aires, Argentina) in their
drinking water for 2 weeks. After all treatments, nonfasting
blood samples were taken and serum was stored at −20∘C
until biochemical evaluation. Commercial kits were used
to measure serum glucose, triglycerides, cholesterol, and
fructosamine. All rats were sacrificed under anaesthesia by
rapid cervical dislocation, after which one femur of each
animal was processed for BMPC isolation and the other for
histomorphometric evaluation, as described in the following
sections.
2.4. Histomorphometric Examination of Long Bones. In order
to evaluate the possible in vivo effect of alendronate on
long bones from diabetic and nondiabetic animals, femora
were processed for quantitative histomorphometric analysis.
Dissected bones were fixed in 10% formalin and decalcified
in 10% EDTA, embedded in paraffin, and 5 𝜇m sections were
obtained with an SM 2000R Leica microtome. The sections
were stained with either tartrate-resistant acid phosphatase
histochemistry (TRAP) (Sigma, Buenos Aires, Argentina)
to specifically identify osteoclasts or hematoxylin-eosin
(H-E). Pictures were taken with a Nikon Coolpix 4500 digital
camera on an Eclipse E400 Nikon microscope. Images were
analyzed using the Image J program with a microscope
scale plugin. In all experimental groups, microarchitecture
of the proximal femoral metaphysis was evaluated by H-E
(relative trabecular volume, bone osteocytic density, and
bone marrow adipocytic density) 250 𝜇m distal from the
cartilage growth plate. Osteoclastic density was determined
in the secondary spongiosa and calculated as positive TRAP
area per square millimeter (Oc/mm2).
2.5. BMPC Isolation and Processing. Bone marrow progen-
itor cells were obtained as we have described previously
[24]. As stated above, BMPC for in vitro experiments were
derived from untreated nondiabetic animals, while those
for ex vivo studies were obtained from C, D, CA, and
DA groups. In each case, unfractioned bone marrow cells
were flushed out of the femoral diaphysis medullary canal
with Dulbecco’s modified essential medium (DMEM) under
sterile conditions. The resulting suspension was seeded in
a 25 cm2 tissue culture flask and incubated in DMEM
supplemented with penicillin (100UI/mL), streptomycin
(100mg/mL), and 10% fetal bovine serum (FBS) (Natocor,
Co´rdoba, Argentina) (basal medium) at 37∘C in a humidified
atmosphere with 5% CO2 and 95% air. Nonadherent cells
were removed by changing the medium after 24 hours. The
culture medium was changed twice a week. When cells
reached confluence (after 10 to 15 days), the cell monolayer
was detached using 0.12% trypsin and 1mM EDTA and
subcultured in tissue culture plates. Cells were then cultured
as described below in different media, in order to induce
their commitment and progression in a lineage-specific
manner.
In the case of in vitro experiments, either control BSA or
AGEs-BSA (with or without 10−8M alendronate) was added
to each differentiation medium during the last 7 days of
culture (for osteogenic and chondrogenic differentiation) or
during the last 3 days (for adipogenic differentiation).
2.6. Osteogenic Differentiation of BMPC. BMPC were plated
at a density of 5 × 104 cells/well in basal medium in
24-well plates and cultured until confluence. Subsequently,
they were induced to differentiate to osteoblasts using an
osteogenic medium (DMEM–10% FBS containing 25mg/mL
ascorbic acid and 5mM sodium beta–glycerol-phosphate)
[24]. Osteoblastic differentiation was evaluated after 15 days
of culture by measuring specific alkaline phosphatase activity
(ALP) and type 1 collagen production and after 21 days by
examination of extracellular calcium deposition.
For ALP evaluation [13], cell monolayers were washed
with phosphate-buffered saline (PBS) and lysed with
250 𝜇L 0.1% Triton-X100. ALP was measured with a
100 𝜇L aliquot of the lysate, by its capacity to hydrolyze
p-nitrophenylphosphate (p-NPP) into p-nitrophenol (p-NP)
at 37∘C for 1 hour. The absorbance of p-NP was recorded
at 405 nm. Aliquots of the same extract were used for
protein determination by Bradford’s technique [25]. Type 1
collagen production was evaluated as reported previously
[24]. Briefly, cell monolayers were fixed with Bouin’s solution
and stained with Sirius red dye for 1 hour. The stained
material was dissolved in 1mL 0.1 N sodium hydroxide,
and the absorbance of the solution was recorded at 550 nm.
Extracellular calcium deposits (mineralization nodules) were
evaluated using Alizarin S red staining [24]. Stained calcium
deposits were extracted with 1mL 0.1 N sodium hydroxide,
recording the optical density at 548 nm.
2.7. Adipogenic Differentiation of BMPC. BMPC were grown
to 50% confluence in 24-well plates in basal medium. Dif-
ferentiation to adipocytes was then induced as described
previously [26]. Briefly, cells were incubated for 10 days with
DMEM–10% FBS supplemented with 0.5mM 3-isobutyl-1-
methylxanthine (IBMX), 1mM dexamethasone (Decadron,
Sidus, Argentina), and 200 nM insulin (Lilly, Buenos Aires,
Argentina). At the end of this culture period the cell
monolayers were lysed with 0.1% Triton-X100. Intracellular
triacylglyceride levels and lipase activity were measured in
the lysate, using commercial kits and according to instruc-
tions of the manufacturer (Wiener, Rosario, Argentina).
Aliquots of the same extract were used for protein deter-
mination by Bradford’s technique [25]. At the end of the
culture period in representative experiments, differentiated
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cells were observed with a contrast-phase microscope and
photographed.
2.8. Chondrogenic Differentiation of BMPC. BMPC were
resuspended at 107 cells/mL in serum-free DMEM. A 10 𝜇L
drop of this suspension was transferred to each well of a
24-well plate and was incubated for 2 hours at 37∘C. After
this, basal medium was added to each well and adhering
cells were cultured for 24 hours. Basal medium was then
discarded and chondrogenic mediumwas added (serum-free
DMEM supplemented with 10 ng/mL TGF-b3 [Peprotech,
USA], 10−8M dexamethasone, insulintransferrin-selenium
(ITS) supplement [Invitrogen, USA]). Cells were cultured for
an additional 21 days, changing the chondrogenic medium
every three days. At the end of this culture period, chon-
drocytic differentiation was evaluated by determination of
chondroitin-sulphate glycosaminoglycan (GAGs) accumula-
tion, as previously described [27]. Briefly, cells were fixed,
stained with 0.5% Alcian blue in 0.1 N HCl, and rinsed
twice with 0.1 N HCl. Cells were finally rinsed with distilled
water and Alcian blue associated with matrix GAGs was
extractedwith 4Mguanidinium-HCl,measuring absorbance
at 600 nm. In representative experiments and after staining
with Alcian blue, differentiated cells were observed with a
contrast-phase microscope and photographed.
2.9. Determination of Intracellular Reactive Oxygen Species
(ROS). As a possible mechanism of action mediating the in
vitro effect of alendronate and/or AGEs on BMPC obtained
from untreated, nondiabetic animals, we measured the
intracellular generation of ROS in BMPC by oxidation of
dihydrorhodamine123 (DHR) to Rhodamine123 (Rho), as we
have previously described [14]. Briefly, cells were cultured for
48 hours in DMEM under different conditions. After these
incubations, culture media was replaced by phenol red-free
DMEMwith 10 𝜇MDHRand the cells were further incubated
for 4 hours. After washing with PBS, the monolayer was
lysated in 0.1% Triton X-100. The concentration of oxidized
product present in the cell extract (Rho) was determined
with a spectrofluorometer (excitation wavelength 495 nm,
emission wavelength 532 nm).
2.10. Western Blot Analysis. BMPC from untreated, nondi-
abetic animals were grown to confluence in 6-well plates
in DMEM–10% FBS and then induced to differentiate to
either osteoblasts or adipocytes as described above (in the
presence of either BSA or AGEs-BSA, with or without 10−8M
alendronate in the culture media). At the end of appropriate
culture periods (15 days for osteogenic induction, 10 days
for adipocytic differentiation), cells were lysed in Laemmli’s
buffer [28]. Lysates were heated to 100∘C for 3 minutes, and
aliquots containing 30mg protein were subjected to 12%
SDS-PAGE. Separated proteins were transferred to PVDF
membranes. After washing and blocking, the membranes
were incubated overnight at 4∘C with an antibody specific
for Cbfa1/Runx2 (Santa Cruz Biotechnology, Santa Cruz,
CA, USA) for evaluation of osteoblastogenesis or against
PPAR𝛾 (Santa Cruz Biotechnology, Santa Cruz, CA, USA)
for evaluation of adipogenesis. In order to normalize results,
all blots were stripped and reprobed with an anti-beta-actin
antibody (Sigma, St. Louis, MO, USA). Blots were developed
by an enhanced chemiluminescence method. The intensity
of the specific bands was quantified by densitometry after
scanning of the photographic film. Images were analyzed
using the Scion beta 2 program ImageJ program (Scion
Corporation, Frederick, MD, USA).
2.11. Statistical Analysis. Results are expressed as the mean ±
standard error of the mean (SEM) and were obtained from
three separate experiments performed in sextuplicate. Differ-
ences between the groups were assessed by one-way analysis
of variance (ANOVA) using the Tukey post hoc test. For
nonnormally distributed data, the nonparametric Kruskal-
Wallis test with the Dunn post hoc test was performed using
GraphPad In Stat version 3.00 (Graph Pad Software, San
Diego, CA, USA). 𝑝 < 0.05 was considered significant for
all statistical analyses.
3. Results
3.1. In Vitro Effects of AGEs and Alendronate on BMPCMulti-
lineage Differentiation. As described above, in this first series
of in vitro experiments, we evaluated the possible effects of
AGEs-BSA and/or alendronate on the osteogenic, chondro-
genic, and adipogenic differentiation of BMPCobtained from
untreated, nondiabetic animals.
To begin with, we evaluated the effect of different concen-
trations of AGEs-BSA on the osteogenic potential of BMPC.
Cells were cultured for one week in an osteogenic medium
and then incubated for another week in the osteogenic
medium plus different doses of either control BSA or AGEs-
BSA. At the end of this incubation period, two markers of
osteoblastic differentiation (type 1 collagen production and
ALP activity) were evaluated. As can be seen in Figures
1(a) and 1(b), 200mg/mL of AGEs significantly decreased
both parameters. Therefore, in subsequent experiments we
adopted this concentration; using a similar experimental
design, BMPC were submitted to a 15- or 21-day osteogenic
differentiation, in which the mediumwas supplemented with
either 200mg/mL control BSA or AGEs-BSA in the absence
or presence of alendronate (10−9, 10−8 or 10−7M) during
the last week. 15-day cultures were used to evaluate type
1 collagen and ALP, and nodules of mineralization were
analyzed in the 21-day cultures. Figures 1(c)–1(e) show that
for the complete range of tested concentrations, both collagen
production andALPwere stimulated by alendronate (Figures
1(c) and 1(d)). In addition, incubation of BMPC with AGEs-
BSA inhibited their ALP and collagen production at all
tested alendronate concentrations. However, although AGEs
reduce collagen and ALP in the presence of alendronate,
their levels in these conditions are still significantly greater
than those observed for control BSA without alendronate.
After 21 days of osteogenic inductionAGEs-BSA significantly
inhibited matrix mineralization and this effect was com-
pletely prevented by 10−8Malendronate (Figure 1(e)). After 15
days of osteogenic differentiation in the conditions described
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Figure 1: Effect of AGEs and/or alendronate on BMPC osteoblastic differentiation. BMPCwere obtained from nondiabetic untreated animals
and cultured in an osteogenic medium with the indicated concentrations of control BSA or AGEs-BSA (200mg/mL if not indicated), with or
without different doses of alendronate (as indicated, or 10−8M if not indicated), for either 15 days (a–d and f) or 21 days (e). Type 1 collagen
production (a and c), alkaline phosphatase activity (b and d), extracellular nodules of mineralization (e), and expression of Runx2 byWestern
blot (f) were evaluated. Results are expressed as the mean ± SEM. (a and b) ∗𝑝 < 0.05 versus 50mg/mL control BSA; (c–f) ∗𝑝 < 0.05 versus
control BSA, #𝑝 < 0.05 versus AGEs-BSA.
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Figure 2: Effect of AGEs and/or alendronate on BMPC adipocytic differentiation. BMPCwere obtained from nondiabetic untreated animals
and cultured for 10 days in an adipogenic medium with 200mg/mL of either control BSA or AGE-BSA, in the presence or absence of 10−8M
alendronate. Contrast-phase images show intracellular lipid droplets of the monolayer exposed to control BSA (a) or AGEs-BSA (b) (Obj.
40x). Intracellular triglyceride accumulation (TG) (c), lipase enzymatic activity (d), and expression of PPAR-𝛾 by Western blot (e) were
evaluated as markers of adipogenic differentiation. Results are expressed as the mean ± SEM. ∗𝑝 < 0.05 versus control BSA; #𝑝 < 0.05 versus
AGEs-BSA.
above, we also evaluated the expression of the osteoblastic
transcription factor Runx2 byWestern blot. As shown in Fig-
ure 1(f), AGEs-BSA on its own induced a decrease in Runx2
expression and coincubation with alendronate prevented this
antiosteogenic effect. AGEs-BSA appeared to enhance the
effect of alendronate on Runx2 expression.
In another set of experiments, BMPCwere induced to dif-
ferentiate towards an adipocytic phenotype. The adipogenic
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Figure 3: Effect of AGEs and/or alendronate on BMPC chondrocytic differentiation. BMPC were obtained from nondiabetic untreated
animals and cultured for 21 days in a chondrogenicmediumwith 200mg/mL of either control BSA or AGE-BSA, in the presence or absence of
10−8M alendronate. Contrast-phase images of Alcian blue staining show intracellular glycosaminoglycans (GAGs) in the monolayer exposed
to control BSA (a) or AGEs-BSA (b) (Obj. 40x). GAGs-associated stain was quantitated as amarker of chondrocytic differentiation (c). Results
are expressed as the mean ± SEM. ∗𝑝 < 0.05 versus control BSA; #𝑝 < 0.05 versus AGEs-BSA.
medium was added with either control BSA or AGEs-BSA
(200mg/mL) and/or 10−8M alendronate. Contrast-phase
microphotographs (Figures 2(a) and 2(b)) show that expo-
sure of BMPC to AGEs-BSA increased their accumulation
of lipid droplets. Using quantitative methods, AGEs-BSA
was also found to significantly increase both intracellular
triglyceride content and lipase enzymatic activity (Figures
2(c) and 2(d)). In the same culture conditions, Western blot
analysis showed thatAGEs-BSA also increased the expression
of the adipogenic factor PPAR-𝛾 (Figure 2(e)). Coincubation
with alendronate prevented all of these in vitro proadipogenic
effects of AGEs on BMPC (Figures 2(c)–2(e)).
In further studies, BMPC were cultured for 21 days
in a chondrogenic medium with the addition of either
control BSA or AGEs-BSA, in the presence or absence of
alendronate. In all cases, chondrocytic differentiation was
evaluated by cell accumulation of Alcian blue-stainable gly-
cosaminoglycans (GAG). Incubation with AGEs-BSA alone
significantly decreased cell-associatedGAG content.This was
observed in contrast-phase microphotographs (Figures 3(a)
and 3(b)) and confirmed by quantitation of GAG-associated
stain (Figure 3(c)). Coincubation with alendronate prevented
the in vitro antichondrogenic effect of AGEs on BMPC
(Figure 3(c)).
3.2. Effect of AGEs and Alendronate on Intracellular Produc-
tion of Reactive Oxygen Species (ROS). Intracellular gener-
ation of ROS is known to mediate certain effects of AGEs,
particularly those that depend on recognition of AGEs by
RAGE, the receptor for AGEs. Thus, we evaluated whether
this signal transduction pathway might be involved in the in
vitromodulation of osteoblastic differentiation byAGEs-BSA
and alendronate. To this end, BMPC were incubated for 48
hours with 200mg/mL of either BSA or AGEs-BSA with or
without 10−8M alendronate and in the presence or absence
of 50 𝜇M vitamin E (as an antioxidant). After this incubation
period, intracellular ROS production was determined by the
dihydrorhodamine123 method. Figure 4 shows that although
intracellular ROS production was significantly greater in the
presence of AGEs-BSA alone, this AGEs-induced increase
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Figure 4: Effect of AGEs, alendronate, and vitamin E on the
intracellular production of reactive oxygen species (ROS). BMPC
were obtained from nondiabetic untreated animals and cultured for
48 hours with 200mg/mL of either control BSA or AGEs-BSA, with
or without 10−8M alendronate, in the presence or absence of 50 𝜇M
vitamin E. ROS production was assessed by the Rhodamine123
method. Results are expressed as the mean ± SEM. ∗𝑝 < 0.05 versus
control BSA; #𝑝 < 0.05 versus BSA ± Ale, vitE, or Ale-vitE.
was completely prevented by coincubation with vitamin E,
alendronate, or both.
3.3. Diabetes-Induced Alterations in Long-Bone Microarchi-
tecture Are Prevented by Oral Treatment with Alendronate.
Insulin-deficiency was induced in rats by successive injec-
tions of streptozotocin and nicotinamide [22, 23]. Evaluation
of their biochemical metabolic profile confirmed the devel-
opment of Diabetes; an increase in glycaemia, fructosamine,
and triglyceridemia was observed (Table 1). After induction
of Diabetes the animals were treated orally with alendronate,
and this did not significantly modify serum biochemical
parameters (Table 1).
The effect of Diabetes and/or alendronate treatment
on femoral microarchitecture was evaluated by quantitative
histomorphometric analysis. Decalcified bone sections were
stained with H-E and evaluated in the secondary spongiosa
to determine relative trabecular area and osteocyte density,
as well as bone marrow adipocyte density. In addition, TRAP
staining was performed to evaluate osteoclasts on bone
surfaces of the secondary spongiosa. Compared to femora
from control rats, those of diabetic rats exhibited a significant
decrease in their trabecular area, osteocytic density, and
TRAP activity, together with a significant increase in the
density of bonemarrow adipocytes (Figures 5(a)–5(d)). Alen-
dronate treatment of diabetic animals completely prevented
the Diabetes-induced decrease in trabecular bone area and
osteocyte number, and it partially prevented the increase in
bone marrow adiposity. As expected, alendronate treatment
greatly inhibited TRAP activity (Figure 5).
3.4. Diabetes-Induced Alterations in BMPC Phenotypic Com-
mitment Are Prevented by Oral Treatment with Alendronate.
Theeffects of insulin-deficientDiabetes and/or oral treatment
with alendronate, on the osteogenic, adipogenic, and chon-
drogenic commitment of BMPC were also studied. BMPC
were obtained from animals of all experimental groups and
incubated with lineage-specific differentiation culture media.
As can be seen in Figure 6, Diabetes induced a significant
decrease in markers of BMPC osteogenic and chondrogenic
potential and an increase in their adipocytic induction.
Specifically, BMPC obtained from diabetic animals (ver-
sus nondiabetic untreated controls) showed (a) lower ALP
activity and extracellular mineral deposits (after 15 and 21
days of osteogenic differentiation, Figures 6(a) and 6(b)),
(b) a decrease in glycosaminoglycan production (after 21
days of chondrogenic differentiation, Figure 6(c)), and (c)
increases in both intracellular triglyceride deposits and lipase
enzymatic activity (after 10 days of adipogenic differenti-
ation, Figures 6(d) and 6(e)). Oral treatment of animals
with alendronate partially or totally prevented all of these
Diabetes-induced dysregulatory effects on BMPCphenotypic
commitment (Figures 6(a)–6(e)).
4. Discussion
Diabetes mellitus (DM) and osteoporosis constitute an im-
portant burden for health care systems worldwide. Over
the past 20 years a considerable body of experimental and
clinical evidence has accumulated, pointing to an association
betweenDMand bone abnormalities that include osteopenia,
osteoporosis, and/or an increased incidence of low-stress
fractures [29, 30]. This Diabetes-induced bone condition,
also termed diabetic osteopathy, is believed to be partly
due to accumulation of AGEs in the bone matrix. AGEs
form inadequate and irreversible cross-links between col-
lagen molecules, altering the biomechanical properties of
bone. AGEs also depress the functionality of osteoblasts and
osteoclasts via recognition by their receptor RAGE, poten-
tially inducing a decrease in bone turnover that can further
increase AGEs accumulation [15, 16]. A deleterious effect of
AGEs on bone marrow cells has also been demonstrated: an
excess of these end products (or of closely related advanced
oxidation protein products) has been shown to increase
the apoptosis and decrease the migration, proliferation, and
osteogenic differentiation of BMPC while increasing their
adipogenic potential [31–34]. In addition, we and other
researchers have found that BMPC isolated from diabetic
rats show an increase in their adipocytic potential and a
decrease in their bone-forming capacity that correlate with
alterations observed in long-bone histomorphometry and
pQCT analysis [35, 36]. The in vitro results of our present
study are compatible with those previous reports; we have
found that AGEs (at doses similar to those found on proteins
from skin and serum of diabetic patients) [37] decrease the
osteogenic and chondrogenic differentiationwhile increasing
the adipocytic commitment of BMPC obtained from control
(nondiabetic untreated) rats. In addition, our present in vivo
and ex vivo results confirm that the induction of insulin-
deficient Diabetes in rats impairs long-bone microarchi-
tecture, while disrupting BMPC multiphenotype potential
(decrease in osteogenesis and chondrogenesis and increase in
adipogenesis).
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Figure 5: Effects of insulin-deficient Diabetes and oral treatment with alendronate on femoral microarchitecture. Diabetic and nondiabetic
(control) animals were either left untreated (groups D and C) or treated for two weeks with 1mg/kg/day of alendronate in their drinking
water (groups DA and CA). Femora from animals of all groups were dissected, processed, and stained with hematoxylin-eosin or tartrate-
resistant acid phosphatase histochemistry (TRAP). Proximal metaphysis was analyzed by quantitative histomorphometry to determine the
following: (a) trabecular bone area, (b) trabecular osteocyte density, (c) relative osteoclastic TRAP activity in the secondary spongiosa, and
(d) bone marrow adipocyte density. Results are expressed as the mean ± SEM. ∗𝑝 < 0.05 versus C; ∗∗𝑝 < 0.001 versus C; #𝑝 < 0.01 versus D;
##𝑝 < 0.001 versus D.
Table 1: Biochemical parameters in nonfasting serum obtained from animals of all experimental groups.
Serum parameter Control Control + alendronate Diabetic Diabetic + alendronate
Glucose [mg/dL] 168 ± 6 175 ± 9 453 ± 40∗ 380 ± 33#&
Triglycerides [mg/dL] 62 ± 7 54 ± 4 134 ± 42# 128 ± 19#
Fructosamine [𝜇mol/L] 120 ± 15 135 ± 13 190 ± 12% 210 ± 16%
Cholesterol [mg/dL] 37 ± 0.8 37 ± 1 51 ± 5# 56 ± 7#
Results are expressed as the mean ± SEM, 𝑛 = 8.
Differences versus C: #𝑝 < 0.05; %𝑝 < 0.01; and ∗𝑝 < 0.001.
Differences versus D: &𝑝 < 0.01.
Alendronate is the most widely used agent for treatment
of postmenopausal osteoporosis.ThisN-BPwith high affinity
for bone matrix shows mostly antiresorptive effects through
its inhibitory action on the mevalonate pathway of osteo-
clasts. By this mechanism it reduces osteoclastic stress fiber
and focal adhesion density, leading to a disruption of the actin
cytoskeleton [38, 39]. However, low doses of alendronate have
also been shown to stimulate osteoblast function in vitro
[20, 40] and to modulate BMPC phenotypic induction by
increasing osteogenesis and decreasing adipogenesis [41–44].
Our present results are in agreement with these previous
studies: in vitro exposure of BMPC to alendronate alone (at
doses that have been reported in the serum and resorption
lacunae of patients treated with this N-BP) [45–47] increased
their osteoblastic differentiation.
It is generally accepted that treatment with alendronate
increases bonemineral density (BMD) and decreases fracture
incidence; however, it also reduces bone tissue remodeling
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Figure 6: Effects of insulin-deficient Diabetes and oral treatment with alendronate on BMPC osteogenic, chondrogenic, and adipogenic
potential. Diabetic and nondiabetic (control) animals were either left untreated (groups D and C) or treated for two weeks with 1mg/kg/day
of alendronate in their drinking water (groups DA and CA). BMPC were obtained from animals of all experimental groups and initially
cultured in a basal medium. After confluence, BMPC were replated and submitted to lineage-specific culture conditions: (a) an osteogenic
medium for 15 days to evaluate alkaline phosphatase enzymatic activity; (b) an osteogenic medium for 21 days to determine extracellular
mineral nodule deposits; (c) a chondrogenic medium for 21 days to quantitate GAGs-associated Alcian blue staining; and an adipogenic
medium for 10 days to measure intracellular triglyceride accumulation; (d) and lipase enzymatic activity (e). Results are expressed as the
mean ± SEM. ∗𝑝 < 0.05 versus C; ∗∗𝑝 < 0.001 versus C; #𝑝 < 0.05 versus D; ##𝑝 < 0.001 versus D.
that could potentially lead to an accumulation of micro-
damage, adversely affecting energy dissipation capabilities
and overall toughness of bone [48]. This reduction in bone
remodeling would also be expected to increase accumulation
of AGEs, and this was investigated by other researchers
in nondiabetic dogs treated for a year with different doses
of alendronate. They found an increase in bone brittleness
and in bone matrix accumulation of AGEs at high doses of
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alendronate, but not at doses equivalent to those used for
the treatment of postmenopausal osteoporosis [48]. Since
Diabetes per se may also decrease bone turnover, the treat-
ment option of diabetic osteopathy with alendronate must
be closely analyzed in order to determine its pertinence
and efficacy (particularly when long-term use of this N-
BP is being considered). Through in vitro studies, we have
previously demonstrated that while alendronate is able to
prevent the antiosteogenic and proapoptotic effects of AGEs
on osteoblasts [20], AGEs and alendronate potentiate each
other to inhibit osteoclastic recruitment and activity [39]. In
a clinical setting, two studies support the use of alendronate
in diabetic patients: on one hand, a 3-year treatment with
alendronate was associated with increased BMD in older
women with type 2 Diabetes mellitus [17], whereas treatment
with this N-BP for 5 years inhibited the decrease in radial
BMD induced by Diabetes [18]. On the other hand, other
researchers have warned that postmenopausal women with
type 2Diabetes could be resistant to long-term treatmentwith
alendronate [19].
In view of this controversy, we have proposed the
main hypothesis of the present study which is as follows:
the deleterious changes in BMPC phenotypic commitment
induced by AGEs accumulated in the bone matrix of an
individual with Diabetes can be prevented by the presence
of therapeutic doses of alendronate in the bone marrow
microenvironment. In addition, these proosteogenic effects
of alendronate on BMPC multilineage potential, in the
context of diabetic osteopathy, will improve bone microar-
chitecture and functionality. Our present in vitro results
support this hypothesis: we have found that exposure of
control BMPC toAGEs induces a decrease in their expression
of the osteoblast-specific transcription factor Runx2, type I
collagen secretion, ALP activity, and extracellular mineral
nodule deposition. However, when AGEs were coincubated
with alendronate this antiosteogenic effect was completely
abrogated. Similar results were observed when BMPC were
induced to differentiate into chondrocytes: incubation with
AGEs decreased their chondrocytic commitment (i.e., GAG
production), whereas coincubation of AGEs with alen-
dronate prevented this deleterious effect. On the contrary,
the adipocytic differentiation of BMPC was potentiated by
AGEs (increased expression of the proadipogenic regulator,
PPAR-𝛾, of intracellular triglycerides and of lipase activity),
an effect that was inhibited when AGEs were coincubated
with alendronate.
This study’s hypothesis is also supported by the results
of our in vivo and ex vivo experiments. As stated above,
development of partially insulin-deficient Diabetes in rats
induced significant alterations in the microarchitecture of
long bones (decreases in femoral metaphysis trabecular bone
area, osteocyte density, and osteoclast TRAP activity and
an increase in bone marrow adiposity). In addition, BMPC
isolated from femora of diabetic rats showed a decrease in
their osteogenic and chondrogenic potential and an increase
in their capacity for adipogenesis. However, oral treatment
of diabetic animals with alendronate prevented all of these
Diabetes-induced effects on femoral microarchitecture and
BMPC multilineage progression.
Intracellular ROS production is known to mediate var-
ious RAGE-dependent effects of AGEs. In an attempt to
define molecular mechanisms that could be operating for
both AGEs and BPs, in our present study we evaluated
the intracellular production of ROS in vitro, with control
BMPC, and found that both vitamin E and alendronate
completely curbed the AGEs-induced increase in ROS pro-
duction. These results are in agreement with our previous
studies with osteoblasts [20] and with reports by other
authors using human umbilical vein endothelial cells [49, 50].
RAGE-dependent intracellular ROS production is a well-
known signal transduction mechanism that leads to NF-
KB activation and expression of various subsets of genes
in different cell types. However, an excessive increase in
ROS production due to AGEs accumulation could induce
an intracellular prooxidative state, promoting an increase
in advanced oxidation protein products and ultimately cell
apoptosis. This may constitute an indirect deleterious effect
of AGEs on BMPC, contributing to the decrease in bone
formation that has been described in experimental models
of Diabetes. The in vitro results for ROS, in our present
study, provide a possible mechanism of action for the in
vivo preventive actions of alendronate on the antiosteogenic
effects of experimental Diabetes: AGEs accumulated on
bone matrix proteins exposed to hyperglycaemia can induce
ROS in nearby BMPC, an effect that could be prevented
by therapeutic doses of alendronate in the bone marrow
microenvironment.
In conclusion, our results suggest that extracellular AGEs
accumulation can alter BMPC fate by an increase in intracel-
lular ROS production, which in turn modulates the expres-
sion of lineage-specific regulatory factors such as Runx2 and
PPAR𝛾, decreasing the osteoblastogenic and chondrogenic
potential of BMPC in favour of adipogenesis. Importantly, all
these AGEs-induced effects on BMPC can be prevented in
vitro by cotreatment with therapeutic doses of alendronate,
effects that are also operative in vivo. All in all, our present
findings support the results of previous reports that show
a beneficial action of alendronate in patients with Diabetes
mellitus and osteoporosis.
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